stockportfolio.pro
Rapport Therapeutics, Inc. (RAPP)
Healthcare · Biotechnology · NasdaqGM
Rapport Therapeutics, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | — | — | — |
| Net income | $-34.79M | $-78.31M | $-111.48M |
| Net margin | — | — | — |
Source: Rapport Therapeutics, Inc. SEC filings (10-K).
Explore 3 years of Rapport Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RAPP in your portfolio →
Rapport Therapeutics, Inc. financial history by metric
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Rapport Therapeutics, Inc. — frequently asked questions
What is Rapport Therapeutics, Inc.'s revenue?
Rapport Therapeutics, Inc. (RAPP) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Rapport Therapeutics, Inc. profitable?
No — RAPP reported a net loss of $-111.48M in fiscal 2025.
What is RAPP's P/E ratio?
Rapport Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Rapport Therapeutics, Inc. have?
As of fiscal year 2025, RAPP carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Rapport Therapeutics, Inc.'s market cap?
Rapport Therapeutics, Inc. (RAPP) has a market capitalization of about $1.70B, based on the latest data in our nightly-refreshed cache.
When does Rapport Therapeutics, Inc.'s fiscal year end?
RAPP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Rapport Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.